London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here


Come to London

video-icon

WATCH to find out why


Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

A large comparative study of a new mulitifocal intraocular Lens with a rotationally asymmetric design and it's predecessor

Poster Details

First Author: D.Kazakos UK

Co Author(s):    J. Venter   S. Schallhorn           

Abstract Details

Purpose:

To compare clinical outcomes of the new generation Lentis LS-313 MPlusX MF30 with the old generation Lentis LS-313 MPlus MF30

Setting:

Multicenter, Optical Express Clinics, UK

Methods:

Study Group 1,734 eyes (MplusX) Inclusion Criteria: • Primary bilateral implantation of MPlusX 3.0 • Treatments dates 6 Jan to 28 Jun 2014 • Completed 1 month clinical visit Control Group 1,420 eyes (Mplus) Inclusion Criteria: • Primary bilateral implantation of MPlus 3.0 • Treatments dates 7 Oct 2013 to 28 Jun 2014 • Completed 1 month clinical visit Exclusion Criteria: -Irregular of high (>1.5D) astigmatism, -Ocular comorbidity (LVC, ARMD, POAG), -Occupational requirements (pilots, drivers, perfectionists) Pre and postoperative data: UDVA, CDVA, monocular UNVA, CNVA, Patient reported outcomes

Results:

Demographics (Mx vs M+): Age(57±7yrs), Male/Female(45/55 vs 47/53), Pre-op CDVA (Logmar): -0.05±0.07 vs -0.04±0.07 Pre-op Myopic Sphere: -2.77±2.15 vs -3.14±2.69 Pre-op Hyperopic Sphere: +1.89±1.49 vs +2.27±1.65 Pre-op Cylinder: -0.56±0.44 vs -0.54±0.40 Myopia/Hyperopia (%): 14/86 vs 15/85 Myopia Low/Mod/High (%): 60/31/9 vs 58/29/13 Post-operative UDVA: >20/20 in 82.9% vs 89.3% p=0.23 Post-operative UNVA monocular: >20/32, 34.4% vs 28.3% p=0.24 Attempted vs achieved (MSE-R2)= 0.95 vs 0.97 MSE mean: -0.15 vs -0.08; <0.5D in 80.2% vs 79.8% Px Satisfaction: 86.4% vs 86% p=0.18 Px improved QoL: 89.9% vs 89.3% Px Recommend Sx: 92.1% vs 91.4%

Conclusions:

A Well matched comparison of over 3,000 eyes No difference between MPlusX and MPlus on: • UCDVA • UCNVA • Refractive predictability • Change in BCVA • Patient Satisfaction • Patient reported quality of vision • Explants • Complications Non statistically significant improvement of near and intermediate vision with associated mild worsening of distance vision was seen and reported in PEQs

Financial Disclosure:

NONE

Back to Poster listing